TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12788675

Group type: EXPERIMENTAL
Intervention: Real world scenario
Number of subjects: 200

Group type: COMPARATOR
Intervention: Television episode scenario
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Higher television viewing
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Viewing of dramas
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Driving under the influence
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Passing out from drinking
Number of subjects: 200
Study: 10867428

Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 38

Group type: COMPARATOR
Intervention: Drilling
Number of subjects: 38
Study: 8630640

Group type: EXPERIMENTAL
Intervention: meloxicam 7.5 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: meloxicam 15 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: piroxicam 20 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 51
Study: 7876657

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (for alteplase)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: c7E3
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (for c7E3)
Number of subjects: 96
Study: 2466520

Group type: EXPERIMENTAL
Intervention: Endoscopically placed biliary endoprosthesis (10 French gauge)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional surgical bypass
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Endoscopically placed biliary endoprosthesis
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Endoscopically placed biliary endoprosthesis and Conventional surgical bypass
Number of subjects: 52
Study: 29609582

Group type: EXPERIMENTAL
Intervention: 3 times/week of 4×4 min AIT at 85‐95% peak heart rate (HRpeak)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: 3 times/week of 1×4 min AIT at 85‐95% HRpeak
Number of subjects: 465

Group type: COMPARATOR
Intervention: 5‐7 times/week of ≥30 min MICT at 60‐70% HRpeak
Number of subjects: 465
Study: 27307665

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg) with ketamine (5 mg/kg) mixed in mango juice (Group MK)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (1 μg/kg) and oral mango juice (Group DX)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intranasal saline and oral mango juice (Group C)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group MK
Number of subjects: 36
Study: 26646670

Group type: EXPERIMENTAL
Intervention: Aerobic high-intensity interval training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computer gaming skills training
Number of subjects: 0
Study: 22901736

Group type: EXPERIMENTAL
Intervention: Vortioxetine 5mg
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 20584595

Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 μg (once daily)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 μg (twice daily)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Fluticasone propionate 200 μg (twice daily)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Fluticasone propionate 375 μg (twice daily)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Fluticasone propionate 500 μg (twice daily)
Number of subjects: 234
Study: 19040374

Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 12
Study: 17256309

Group type: EXPERIMENTAL
Intervention: Pilocarpine lozenge (5 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pilocarpine lozenge (3 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Salagen tablet (control)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo lozenge (control)
Number of subjects: 33
Study: 12729178

Group type: EXPERIMENTAL
Intervention: Theoretically constructed educational intervention
Number of subjects: 0
Study: 10781472

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (20 microg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous ondansetron (4 mg)
Number of subjects: 30
Study: 8618581

Group type: COMPARATOR
Intervention: Intensive chemotherapy (117 patients)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Autologous transplantation (115 patients)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Nonrandomized intensive chemotherapy (189 patients)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Histocompatible bone marrow transplant from a sibling (contemporaneous group)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Autologous transplantation
Number of subjects: 343
Study: 1621752

Group type: EXPERIMENTAL
Intervention: Loracarbef (400 mg twice daily)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Cefaclor (500 mg three times daily)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Norfloxacin (400 mg twice daily)
Number of subjects: 245
Study: 6331150

Group type: COMPARATOR
Intervention: 17 g bran (B)
Number of subjects: 5

Group type: COMPARATOR
Intervention: 18 g bran and fruit (BF)
Number of subjects: 5
Study: 31614357

Group type: EXPERIMENTAL
Intervention: Non‐transecting bilayer substitution urethroplasty
Number of subjects: 21
Study: 29798142

Group type: EXPERIMENTAL
Intervention: We‐Media management (Group A)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Telephone management (Group B)
Number of subjects: 180
Study: 26282839

Group type: EXPERIMENTAL
Intervention: Morning tobramycin dosing (0800 h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Evening tobramycin dosing (2000 h)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both morning and evening dosing
Number of subjects: 18
Study: 24355995

Group type: EXPERIMENTAL
Intervention: Aerobic training (AT) using a cycle ergometer (n = 13)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (RT) using training machines (n = 14)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Low-intensity sham training of the arms (C) (n = 16)
Number of subjects: 43
Study: 23151126

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (combined exercise and dietary advice)
Number of subjects: 12
Study: 19597720

Group type: EXPERIMENTAL
Intervention: Zinc-supplemented sportsmen group (group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Zinc-supplemented sedentary group (group 3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sportsmen group without supplementation (group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sedentary group without supplementation (group 4)
Number of subjects: 40
Study: 17375732

Group type: EXPERIMENTAL
Intervention: 16-week couples group
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: 16-week fathers group
Number of subjects: 257

Group type: COMPARATOR
Intervention: Single-session control group
Number of subjects: 257
Study: 16381265

Group type: EXPERIMENTAL
Intervention: Wound instillation Group A1 (diclofenac IM)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Wound instillation Group A2 (diclofenac suppository)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-wound instillation Group B1 (diclofenac IM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-wound instillation Group B2 (diclofenac suppository)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Wound instillation groups (A1, A2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-wound instillation groups (B1, B2)
Number of subjects: 100
Study: 12414865

Group type: EXPERIMENTAL
Intervention: Rapeseed oil diet (rich in monounsaturated fatty acids and alpha-linolenic acid)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Olive oil diet (rich in monounsaturated fatty acids)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sunflower oil diet (rich in n‐6‐polyunsaturated fatty acids)
Number of subjects: 55
Study: 9526148

Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gas
Number of subjects: 0
Study: 9324693

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Fibrinolytic agents (other patients)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Complete recanalization (TIMI 3)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Absent or incomplete recanalization (TIMI 0-2)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Ejection fraction < 50%
Number of subjects: 575
Study: 2692810

Group type: EXPERIMENTAL
Intervention: Lisuride (1.2-2.4 mg/day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Lisuride (0.15 mg/day)
Number of subjects: 2
Study: 90412

Group type: EXPERIMENTAL
Intervention: Synchronized slide audiotape series on caries prophylaxis
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Synchronized slide audiotape series
Number of subjects: 200

Group type: COMPARATOR
Intervention: Simple verbal instruction
Number of subjects: 200
Study: 31961490

Group type: EXPERIMENTAL
Intervention: Incredible Years® Autism Spectrum and Language Delays (IY‐ASLD) parent program delivered once a week for 12 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Wait-list, treatment as usual control condition
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Exploratory outcome analyses
Number of subjects: 58
Study: 30458340

Group type: EXPERIMENTAL
Intervention: nal-IRI+5-FU/LV
Number of subjects: 128

Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 128
Study: 29099406

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Narrative Cognitive Therapy (NCT)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Intention-to-treat analysis
Number of subjects: 97
Study: 25759095

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannulae (HFNC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (CPAP)
Number of subjects: 10
Study: 24300609

Group type: EXPERIMENTAL
Intervention: Warmed, humidified CO2
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard CO2 insufflation
Number of subjects: 150
Study: 20728083

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 600 μg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 μg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 75
Study: 19637103

Group type: EXPERIMENTAL
Intervention: Cocaine/Stimulant use
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Opioid use
Number of subjects: 214
Study: 16713344

Group type: EXPERIMENTAL
Intervention: Ropinirole (exact dosage and duration not specified)
Number of subjects: 550
Study: 15457381

Group type: EXPERIMENTAL
Intervention: AESOP 3000 robot system
Number of subjects: 240

Group type: COMPARATOR
Intervention: Assistant group (control)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Surgeon subjective evaluation
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: AESOP usage
Number of subjects: 240
Study: 11304774

Group type: EXPERIMENTAL
Intervention: Accelerated-intensified CEF (HD-CEF14) with G-CSF (cyclophosphamide 1,000 mg/m(2), epirubicin 80 mg/m(2), fluorouracil 600 mg/m(2), administered every 14 days)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard CEF (CEF21) (cyclophosphamide 600 mg/m(2), epirubicin 60 mg/m(2), fluorouracil 600 mg/m(2), administered every 21 days)
Number of subjects: 151
Study: 9031302

Group type: EXPERIMENTAL
Intervention: High-viscosity viscoelastic (HVV)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Low-viscosity viscoelastic (LVV)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Phacoemulsification (PHACO)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Manual nucleofragmentation (MNF)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Extracapsular cataract extraction (ECCE)
Number of subjects: 74
Study: 8290746

Group type: EXPERIMENTAL
Intervention: E2H9R9 regimen (9 months)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Z2H9R9 regimen (9 months)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Z2H6R6 regimen (6 months)
Number of subjects: 199
Study: 3318902

Group type: EXPERIMENTAL
Intervention: Adriamycin 70 mg m‐2 i.v. 3‐weekly for 8 cycles (Regimen A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Adriamycin 35 mg m‐2 i.v. 3‐weekly for 16 courses (Regimen B)
Number of subjects: 48
Study: 29160597

Group type: EXPERIMENTAL
Intervention: Exercise training combined with psychosocial intervention
Number of subjects: 128

Group type: COMPARATOR
Intervention: Exercise training alone
Number of subjects: 128
Study: 27323446

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (twice a week) and Acetylcysteine capsule (200 mg/time, t.i.d.) for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acetylcysteine capsule (200 mg/time, t.i.d.) for 12 weeks
Number of subjects: 120
Study: 25147155

Group type: EXPERIMENTAL
Intervention: Resistant starch (n=28)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control starch (n=28)
Number of subjects: 56
Study: 22458987

Group type: EXPERIMENTAL
Intervention: 12-month collaborative care intervention (problem-solving therapy and/or pharmacotherapy, telephone symptom monitoring/relapse prevention, behavioral activation and patient navigation support)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 193
Study: 20039955

Group type: EXPERIMENTAL
Intervention: Medication-overuse headache (MOH)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Episodic headache (EH)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Medication-overuse headache (MOH) and episodic headache (EH)
Number of subjects: 219
Study: 18930093

Group type: EXPERIMENTAL
Intervention: Intraderal TIV (0.1 ml injection, 9 microg HA/strain)
Number of subjects: 978

Group type: COMPARATOR
Intervention: Intramuscular vaccine (0.5 ml injection, 15 microg HA/strain)
Number of subjects: 978
Study: 17444098

Group type: EXPERIMENTAL
Intervention: Corneal topography-guided clear corneal tunnel phacoemulsification and IOL implantation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional temporal corneal tunnel phacoemulsification and IOL implantation
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Corneal topography-guided clear corneal tunnel phacoemulsification
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional temporal corneal tunnel phacoemulsification
Number of subjects: 37
Study: 14616872

Group type: EXPERIMENTAL
Intervention: Lower fat peanut challenge vehicle (22.9% fat)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Higher fat peanut challenge vehicle (31.5% fat)
Number of subjects: 4
Study: 10758950

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG) in patients with treated diabetes mellitus
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA) in patients with treated diabetes mellitus
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG) in nondiabetic patients
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA) in nondiabetic patients
Number of subjects: 1829
Study: 9162315

Group type: EXPERIMENTAL
Intervention: Treatment of pulmonary tuberculosis
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (patients with non granulomatous diseases)
Number of subjects: 42
Study: 1564581

Group type: EXPERIMENTAL
Intervention: OH-CBL (computer-based learning program)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lecture group (control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: OH-CBL
Number of subjects: 80
Study: 3925656

Group type: EXPERIMENTAL
Intervention: 800 mg nitroglycerin ointment 2%
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31562872

Group type: EXPERIMENTAL
Intervention: Lateral push-off skater exercise
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional treadmill training
Number of subjects: 36
Study: 30215593

Group type: EXPERIMENTAL
Intervention: Hydromorphone alone (group 2)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Bupivacaine with hydromorphone (group 3)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Epidural placebo (group 1)
Number of subjects: 99
Study: 28073199

Group type: EXPERIMENTAL
Intervention: Mixture of 2.5% lidocaine and 2.5% prilocaine (Group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intrarectal local anesthetic administration (lidocaine 5 ml 10%) and lidocaine local spray 15% (Group B)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Periprostatic block anesthesia (lidocaine 10 ml 10%) (Group C)
Number of subjects: 150
Study: 24359138

Group type: EXPERIMENTAL
Intervention: Combination of intraligamentary injection + buccal infiltration + IANB
Number of subjects: 82

Group type: COMPARATOR
Intervention: Traditional IANB injection
Number of subjects: 82
Study: 22549666

Group type: EXPERIMENTAL
Intervention: Guided surgery with semicircular miniflap technique
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 24
Study: 20332351

Group type: EXPERIMENTAL
Intervention: Once-daily liraglutide (1.8 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuing liraglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice-daily exenatide (10 microg)
Number of subjects: 0
Study: 18334461

Group type: EXPERIMENTAL
Intervention: Occlusive hydrocolloid dressing (OHD; Karayahesive)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Gauze dressing (GD)
Number of subjects: 134
Study: 15716701

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Plasma of nebivolol-treated patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 20
Study: 12105827

Group type: EXPERIMENTAL
Intervention: Gastroenterologist-administered propofol
Number of subjects: 75

Group type: COMPARATOR
Intervention: Meperidine/midazolam
Number of subjects: 75
Study: 10432168

Group type: EXPERIMENTAL
Intervention: Benfluorex (150 mg t.i.d.)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 127
Study: 8523379

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Quinapril (10-40 mg/day)
Number of subjects: 27
Study: 2301902

Group type: EXPERIMENTAL
Intervention: Isotope limb blood flow measurement
Number of subjects: 25
Study: 6458582

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg body weight 13‐cis‐retinoic acid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg body weight 13‐cis‐retinoic acid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg body weight 13‐cis‐retinoic acid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 13‐cis‐retinoic acid
Number of subjects: 13
Study: 31926152

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (60,000 IU fortnightly for 12 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30382728

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 27903087

Group type: EXPERIMENTAL
Intervention: Same-day cervical preparation with osmotic dilator and misoprostol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Overnight cervical preparation with osmotic dilator and misoprostol
Number of subjects: 70
Study: 25745875

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg
Number of subjects: 122

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 122

Group type: COMPARATOR
Intervention: Sham/intravitreal aflibercept
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 122

Group type: COMPARATOR
Intervention: Intravitreal aflibercept and Sham
Number of subjects: 122
Study: 23342996

Group type: EXPERIMENTAL
Intervention: MSP142 vaccine (50 μg) administered intramuscularly with adjuvant system AS01
Number of subjects: 56

Group type: COMPARATOR
Intervention: Rabies vaccine (control)
Number of subjects: 56
Study: 21696307

Group type: EXPERIMENTAL
Intervention: Telaprevir combined with peginterferon alfa-2a and ribavirin for 12 weeks (T12PR group)
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Telaprevir with peginterferon-ribavirin for 8 weeks and placebo with peginterferon-ribavirin for 4 weeks (T8PR group)
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Placebo with peginterferon-ribavirin for 12 weeks (PR group)
Number of subjects: 1088
Study: 19232112

Group type: EXPERIMENTAL
Intervention: Informed choice invitation
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Standard invitation
Number of subjects: 1500
Study: 17854661

Group type: EXPERIMENTAL
Intervention: APC I1307K allele in colorectal cancer patients (n=56)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: APC I1307K allele in stomach cancer patients (n=57)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: APC I1307K carriers
Number of subjects: 113

Group type: COMPARATOR
Intervention: APC I1307K allele
Number of subjects: 113
Study: 15078748

Group type: EXPERIMENTAL
Intervention: Fexofenadine (FEX), 180 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Montelukast (ML), 10 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study: 11346140

Group type: EXPERIMENTAL
Intervention: Omeprazole, clarithromycin, and metronidazole
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Omeprazole, clarithromycin, and amoxycillin
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Omeprazole, clarithromycin, and metronidazole (per protocol)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Omeprazole, clarithromycin, and amoxycillin (per protocol)
Number of subjects: 221
Study: 9588608

Group type: EXPERIMENTAL
Intervention: Exercise training (five 45‐min walking sessions/wk at 60‐75% maximum heart rate)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Moderate energy restriction (4.19‐5.44 MJ or 1,200‐1,300 kcal x d(‐1))
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Exercise and diet (combined intervention)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no exercise, no diet)
Number of subjects: 91